Journal of Neuro-Oncology

, Volume 87, Issue 3, pp 247–253 | Cite as

Tyrosine kinase expression in pediatric high grade astrocytoma

  • Muh-Lii Liang
  • Jing Ma
  • Michael Ho
  • Lauren Solomon
  • Eric Bouffet
  • James T. Rutka
  • Cynthia Hawkins
Lab.Investigation-Human/Animal Tissue

Abstract

The over-expression of several receptor tyrosine kinases in adult high grade astrocytomas (HGA) led to trials of tyrosine kinase inhibitors in these patients. Similar molecular genetic analysis of pediatric HGA is only beginning to be published. Thus it is unclear to what degree these pathways are also involved in the pediatric age group and whether they may also serve as useful therapeutic targets for children with HGAs. Here we investigated the protein expression profile of a series of pediatric HGAs. Following institutional ethical approval, clinical information and tumor samples were obtained for 42 HGA patients. Mean age at presentation was 10.1 years (range 0.13–19.3 years). OS was 12% and PFS was 3.7%. Extent of resection was associated with improved PFS (P = 0.0015) with a trend towards improved OS (P = 0.08). There was no significant effect of age or adjuvant therapy use on PFS or OS. Immunopositivity for each of the markers was as follows: p53 35%; PDGFR-α 45%; PDGFR-β 31%; PTEN 67%; EGFR wild type 58%; EGFRvIII 2%. No significant effect on OS or PFS was found for any of the markers by log rank analysis. However, all long-term survivors expressed PTEN and were EGFRvIII negative. Further, there were distinct differences in protein expression between pediatric and adult HGAs suggesting that EGFR kinase inhibitors may not be beneficial for treatment of HGA in the pediatric age group and pointing to the need to study pediatric astrocytomas as distinct entities from adult astrocytomas.

Keywords

Epidermal growth factor receptor Platelet-derived growth factor receptor Pediatric astrocytoma Phosphatase Tensin homolog 

References

  1. 1.
    Broniscer A, Gajjar A (2004) Supratentorial high-grade astrocytoma and diffuse brainstem glioma: two challenges for the pediatric oncologist. Oncologist 9:197–206PubMedCrossRefGoogle Scholar
  2. 2.
    Kleihues P, Sobin LH (2000) World Health Organization classification of tumors. Cancer 88:2887PubMedCrossRefGoogle Scholar
  3. 3.
    Camp RL, Charette LA, Rimm DL (2000) Validation of tissue microarray technology in breast carcinoma. Lab Invest 80:1943–1949PubMedGoogle Scholar
  4. 4.
    Pollack IF, Finkelstein SD, Woods J, Burnham J, Holmes EJ, Hamilton RL, Yates AJ, Boyett JM, Finlay JL, Sposto R (2002) Expression of p53 and prognosis in children with malignant gliomas. N Engl J Med 346:420–427PubMedCrossRefGoogle Scholar
  5. 5.
    Wilczynski SP, Chen YY, Chen W, Howell SB, Shively JE, Alberts DS (2005) Expression and mutational analysis of tyrosine kinase receptors c-kit, PDGFRalpha, and PDGFRbeta in ovarian cancers. Hum Pathol 36:242–249PubMedCrossRefGoogle Scholar
  6. 6.
    Mellinghoff IK, Wang MY, Vivanco I, Haas-Kogan DA, Zhu S, Dia EQ, Lu KV, Yoshimoto K, Huang JH, Chute DJ, Riggs BL, Horvath S, Liau LM, Cavenee WK, Rao PN, Beroukhim R, Peck TC, Lee JC, Sellers WR, Stokoe D, Prados M, Cloughesy TF, Sawyers CL, Mischel PS (2005) Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N Engl J Med 353:2012–2024PubMedCrossRefGoogle Scholar
  7. 7.
    Choe G, Horvath S, Cloughesy TF, Crosby K, Seligson D, Palotie A, Inge L, Smith BL, Sawyers CL, Mischel PS (2003) Analysis of the phosphatidylinositol 3’-kinase signaling pathway in glioblastoma patients in vivo. Cancer Res 63:2742–2746PubMedGoogle Scholar
  8. 8.
    Pollack IF (1994) Brain tumors in children. N Engl J Med 331:1500–1507PubMedCrossRefGoogle Scholar
  9. 9.
    Raffel C, Frederick L, O’Fallon JR, Atherton-Skaff P, Perry A, Jenkins RB, James CD (1999) Analysis of oncogene and tumor suppressor gene alterations in pediatric malignant astrocytomas reveals reduced survival for patients with PTEN mutations. Clin Cancer Res 5:4085–4090PubMedGoogle Scholar
  10. 10.
    Nicholson HS, Krailo M, Ames MM, Seibel NL, Reid JM, Liu-Mares W, Vezina LG, Ettinger AG, Reaman GH (1998) Phase I study of temozolomide in children and adolescents with recurrent solid tumors: a report from the Children’s Cancer Group. J Clin Oncol 16:3037–3043PubMedGoogle Scholar
  11. 11.
    Wisoff JH, Boyett JM, Berger MS, Brant C, Li H, Yates AJ, McGuire-Cullen P, Turski PA, Sutton LN, Allen JC, Packer RJ, Finlay JL (1998) Current neurosurgical management and the impact of the extent of resection in the treatment of malignant gliomas of childhood: a report of the Children’s Cancer Group trial no. CCG-945. J Neurosurg 89:52–59PubMedGoogle Scholar
  12. 12.
    Bucci MK, Maity A, Janss AJ, Belasco JB, Fisher MJ, Tochner ZA, Rorke L, Sutton LN, Phillips PC, Shu HK (2004) Near complete surgical resection predicts a favorable outcome in pediatric patients with nonbrainstem, malignant gliomas: results from a single center in the magnetic resonance imaging era. Cancer 101:817–824PubMedCrossRefGoogle Scholar
  13. 13.
    Ganigi PM, Santosh V, Anandh B, Chandramouli BA, Sastry Kolluri VR (2005) Expression of p53, EGFR, pRb and bcl-2 proteins in pediatric glioblastoma multiforme: a study of 54 patients. Pediatr Neurosurg 41:292–299PubMedCrossRefGoogle Scholar
  14. 14.
    Ribom D, Andrae J, Frielingsdorf M, Hartman M, Nister M, Smits A (2002) Prognostic value of platelet derived growth factor alpha receptor expression in grade 2 astrocytomas and oligoastrocytomas. J Neurol Neurosurg Psychiatry 72:782–787PubMedCrossRefGoogle Scholar
  15. 15.
    Haberler C, Gelpi E, Marosi C, Rossler K, Birner P, Budka H, Hainfellner JA (2006) Immunohistochemical analysis of platelet-derived growth factor receptor-alpha, -beta, c-kit, c-abl, and arg proteins in glioblastoma: possible implications for patient selection for imatinib mesylate therapy. J Neurooncol 76:105–109PubMedCrossRefGoogle Scholar
  16. 16.
    Guo P, Hu B, Gu W, Xu L, Wang D, Huang HJ, Cavenee WK, Cheng SY (2003) Platelet-derived growth factor-B enhances glioma angiogenesis by stimulating vascular endothelial growth factor expression in tumor endothelia and by promoting pericyte recruitment. Am J Pathol 162:1083–1093PubMedGoogle Scholar
  17. 17.
    Korshunov A, Golanov A, Sycheva R, Pronin I (1999) Prognostic value of tumour associated antigen immunoreactivity and apoptosis in cerebral glioblastomas: an analysis of 168 cases. J Clin Pathol 52:574–580PubMedGoogle Scholar
  18. 18.
    Idoate MA, Soria E, Lozano MD, Sola JJ, Panizo A, de Alava E, Manrique M, Pardo-Mindan FJ (2003) PTEN protein expression correlates with PTEN gene molecular changes but not with VEGF expression in astrocytomas. Diagn Mol Pathol 12:160–165PubMedGoogle Scholar
  19. 19.
    Heimberger AB, Hlatky R, Suki D, Yang D, Weinberg J, Gilbert M, Sawaya R, Aldape K (2005) Prognostic effect of epidermal growth factor receptor and EGFRvIII in glioblastoma multiforme patients. Clin Cancer Res 11:1462–1466PubMedCrossRefGoogle Scholar
  20. 20.
    Sano T, Lin H, Chen X, Langford LA, Koul D, Bondy ML, Hess KR, Myers JN, Hong YK, Yung WK, Steck PA (1999) Differential expression of MMAC/PTEN in glioblastoma multiforme: relationship to localization and prognosis. Cancer Res 59:1820–1824PubMedGoogle Scholar
  21. 21.
    Chakravarti A, Delaney MA, Noll E, Black PM, Loeffler JS, Muzikansky A, Dyson NJ (2001) Prognostic and pathologic significance of quantitative protein expression profiling in human gliomas. Clin Cancer Res 7:2387–2395PubMedGoogle Scholar
  22. 22.
    Lin H, Bondy ML, Langford LA, Hess KR, Delclos GL, Wu X, Chan W, Pershouse MA, Yung WK, Steck PA (1998) Allelic deletion analyses of MMAC/PTEN and DMBT1 loci in gliomas: relationship to prognostic significance. Clin Cancer Res 4:2447–2454PubMedGoogle Scholar
  23. 23.
    Sure U, Ruedi D, Tachibana O, Yonekawa Y, Ohgaki H, Kleihues P, Hegi ME (1997) Determination of p53 mutations, EGFR overexpression, and loss of p16 expression in pediatric glioblastomas. J Neuropathol Exp Neurol 56:782–789PubMedCrossRefGoogle Scholar
  24. 24.
    Bredel M, Pollack IF, Hamilton RL, James CD (1999) Epidermal growth factor receptor expression and gene amplification in high-grade non-brainstem gliomas of childhood. Clin Cancer Res 5:1786–1792PubMedGoogle Scholar
  25. 25.
    Heimberger AB, Suki D, Yang D, Shi W, Aldape K (2005) The natural history of EGFR and EGFRvIII in glioblastoma patients. J Transl Med 3:38PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC. 2008

Authors and Affiliations

  • Muh-Lii Liang
    • 1
    • 2
    • 3
  • Jing Ma
    • 3
    • 4
  • Michael Ho
    • 4
  • Lauren Solomon
    • 3
    • 4
  • Eric Bouffet
    • 5
  • James T. Rutka
    • 3
    • 6
  • Cynthia Hawkins
    • 3
    • 4
  1. 1.Department of Neurosurgery, Neurological InstituteTaipei Veterans General HospitalTaipeiTaiwan, ROC
  2. 2.National Yang-Ming University School of MedicineTaipeiTaiwan, ROC
  3. 3.Arthur and Sonia Labatt Brain Tumour Research CentreHospital for Sick ChildrenTorontoCanada
  4. 4.Division of Pathology, Department of Paediatric Laboratory MedicineHospital for Sick ChildrenTorontoCanada
  5. 5.Division of OncologyHospital for Sick ChildrenTorontoCanada
  6. 6.Division of NeurosurgeryHospital for Sick ChildrenTorontoCanada

Personalised recommendations